Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Avertix’s Guardian System is the first and only FDA-approved implantable device for real-time detection and alerting of heart attacks—including silent myocardial infarctions—in high-risk patients. Clinical data from the pivotal ALERTS trial demonstrated that the system enables earlier hospital arrival and intervention compared to standard care. Recent cost-effectiveness analysis shows an incremental cost-effectiveness ratio of $58,668 per QALY gained versus current practice—comparable to other implantable cardiac technologies. The Guardian System has been granted favorable CMS reimbursement status.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Avertix Medical.